PapersFlow Research Brief
Adrenal and Paraganglionic Tumors
Research Guide
What is Adrenal and Paraganglionic Tumors?
Adrenal and paraganglionic tumors are rare neuroendocrine neoplasms arising from chromaffin cells in the adrenal medulla as pheochromocytomas or from extra-adrenal paraganglia as paragangliomas, often associated with genetic mutations and requiring specific biochemical and imaging diagnosis for clinical management.
Research on adrenal and paraganglionic tumors encompasses 59,296 works focused on pheochromocytoma, paraganglioma, genetic mutations, clinical management, adrenal incidentalomas, biochemical diagnosis, succinate dehydrogenase, adrenocortical carcinoma, imaging characteristics, and molecular classification. Key guidelines recommend initial biochemical testing with plasma free or urinary fractionated metanephrines for pheochromocytoma and paraganglioma, with follow-up for positive results as outlined in 'Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline' (2014). Mutations in SDHD, a mitochondrial complex II gene, link hereditary paraganglioma to oxygen sensing pathways, as shown in 'Mutations in SDHD, a Mitochondrial Complex II Gene, in Hereditary Paraganglioma' (2000).
Topic Hierarchy
Research Sub-Topics
Pheochromocytoma Genetic Mutations
This sub-topic investigates germline and somatic mutations driving pheochromocytoma tumorigenesis, with emphasis on SDHx and VHL genes. Researchers perform genomic sequencing and functional studies to classify hereditary syndromes.
Paraganglioma Molecular Classification
This sub-topic develops and refines molecular subtypes of paragangliomas based on hypoxia pathways, methylation profiles, and transcriptomics. Researchers correlate classifications with clinical behavior using multi-omics datasets.
Biochemical Diagnosis of Adrenal Tumors
This sub-topic evaluates plasma and urinary metanephrines, catecholamines, and novel biomarkers for accurate diagnosis of functional adrenal masses. Researchers conduct prospective validation studies and guideline updates.
Imaging Characteristics of Paragangliomas
This sub-topic analyzes MRI, CT, and functional imaging patterns to differentiate paragangliomas from other retroperitoneal tumors. Researchers develop radiomics models and AI algorithms for preoperative planning.
Clinical Management of Adrenal Incidentalomas
This sub-topic covers algorithms for risk assessment, hormonal workup, and indications for adrenalectomy in incidentalomas. Researchers perform meta-analyses of outcomes and long-term follow-up studies.
Why It Matters
Adrenal and paraganglionic tumors impact clinical endocrinology and oncology through precise diagnosis and treatment of catecholamine-secreting tumors that can cause hypertension and cardiovascular complications. 'Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline' by Lenders et al. (2014) provides evidence-based recommendations for biochemical testing with plasma free or urinary fractionated metanephrines, reducing false positives from preanalytical factors and guiding surgical management in over 2,668 cited cases. Genetic discoveries like SDHD mutations in hereditary paraganglioma, reported by Baysal et al. (2000) with 1,629 citations, enable familial screening and tumor surveillance, while succinate dehydrogenase dysfunction inhibiting HIF-α prolyl hydroxylase, per Selak et al. (2005), explains oncogenesis in these tumors affecting patient prognosis in surgical and medical settings.
Reading Guide
Where to Start
'Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline' by Lenders et al. (2014) is the first paper to read because it offers consensus recommendations on biochemical testing, diagnosis, and management suitable for clinical orientation.
Key Papers Explained
'Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline' by Lenders et al. (2014) establishes diagnostic protocols using metanephrines, building on genetic insights from 'Mutations in SDHD, a Mitochondrial Complex II Gene, in Hereditary Paraganglioma' by Baysal et al. (2000), which identifies SDHD as PGL1 causing carotid body tumors. 'Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase' by Selak et al. (2005) mechanistically connects SDH mutations to HIF stabilization, explaining tumor hypoxia response. 'Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway' by Kaelin and Ratcliffe (2008) provides the broader oxygen-sensing framework underpinning these tumor pathways.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research emphasizes molecular classification of succinate dehydrogenase-deficient paragangliomas and imaging for metastatic potential, extending diagnostic guidelines from Lenders et al. (2014) with genetic profiling from Baysal et al. (2000) and mechanistic studies like Selak et al. (2005).
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | 1994 Consensus Conference on Acute GVHD Grading. | 1995 | PubMed | 5.1K | ✕ |
| 2 | Oxygen Sensing by Metazoans: The Central Role of the HIF Hydro... | 2008 | Molecular Cell | 3.1K | ✓ |
| 3 | The Management of Primary Aldosteronism: Case Detection, Diagn... | 2016 | The Journal of Clinica... | 2.8K | ✓ |
| 4 | Pheochromocytoma and Paraganglioma: An Endocrine Society Clini... | 2014 | The Journal of Clinica... | 2.7K | ✓ |
| 5 | The Diagnosis of Cushing's Syndrome: An Endocrine Society Clin... | 2008 | The Journal of Clinica... | 2.6K | ✓ |
| 6 | Succinate links TCA cycle dysfunction to oncogenesis by inhibi... | 2005 | Cancer Cell | 2.0K | ✓ |
| 7 | The International Neuroblastoma Risk Group (INRG) Classificati... | 2008 | Journal of Clinical On... | 1.8K | ✓ |
| 8 | Diagnosis and Treatment of Hyperprolactinemia: An Endocrine So... | 2011 | The Journal of Clinica... | 1.8K | ✓ |
| 9 | Cushing's syndrome | 2015 | The Lancet | 1.7K | ✕ |
| 10 | Mutations in <i>SDHD</i> , a Mitochondrial Complex II Gene, in... | 2000 | Science | 1.6K | ✕ |
Frequently Asked Questions
What is the recommended initial biochemical testing for pheochromocytoma and paraganglioma?
Initial biochemical testing for pheochromocytoma and paraganglioma (PPGLs) should include measurements of plasma free or urinary fractionated metanephrines. Preanalytical factors that lead to false-positive or false-negative results must be considered. All positive results require follow-up confirmation, as stated in 'Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline' by Lenders et al. (2014).
How do SDHD mutations contribute to hereditary paraganglioma?
Mutations in SDHD, a mitochondrial complex II gene, cause hereditary paraganglioma characterized by benign, vascularized tumors in the head and neck, most commonly at the carotid body. These mutations link to oxygen sensing in blood via the PGL1 gene in affected families. This is detailed in 'Mutations in SDHD, a Mitochondrial Complex II Gene, in Hereditary Paraganglioma' by Baysal et al. (2000).
What role does succinate play in adrenal and paraganglionic tumor oncogenesis?
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. This mechanism promotes tumor development in succinate dehydrogenase-related paragangliomas. Findings are from 'Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase' by Selak et al. (2005).
Why test for pheochromocytoma in adrenal incidentalomas?
Adrenal incidentalomas require evaluation for pheochromocytoma due to risks of catecholamine excess and surgical complications. Biochemical testing with metanephrines is standard, aligning with guidelines for functional tumor assessment. This connects to protocols in 'Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline' by Lenders et al. (2014).
What is the genetic basis of paraganglioma linked to oxygen sensing?
Paraganglioma involves succinate dehydrogenase mutations disrupting mitochondrial function and oxygen sensing via HIF pathways. SDHD mutations specifically drive hereditary forms at chemoreceptive sites like the carotid body. Evidence comes from 'Mutations in SDHD, a Mitochondrial Complex II Gene, in Hereditary Paraganglioma' by Baysal et al. (2000) and related works.
Open Research Questions
- ? How can preanalytical factors in metanephrine testing be standardized to minimize false positives in paraganglioma diagnosis?
- ? What are the precise mechanisms by which SDHD mutations alter HIF hydroxylase activity in paraganglioma oncogenesis?
- ? Which molecular imaging modalities best differentiate metastatic pheochromocytoma from benign adrenal incidentalomas?
- ? How do succinate accumulation effects on TCA cycle integrate with clinical risk stratification in succinate dehydrogenase-deficient tumors?
- ? What genetic modifiers influence penetrance of hereditary paraganglioma syndromes beyond SDHD?
Recent Trends
The field maintains steady research volume at 59,296 works with focus on pheochromocytoma, paraganglioma, succinate dehydrogenase mutations, and biochemical diagnosis, as no growth rate data over 5 years is available and no recent preprints or news in the last 12 months indicate ongoing reliance on established guidelines like Lenders et al. and genetic foundations from Baysal et al. (2000).
2014Research Adrenal and Paraganglionic Tumors with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Adrenal and Paraganglionic Tumors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers